Targeted Therapies In Asthma: Update Bulletin [April 2016]

Targeted Therapies In Asthma: Update Bulletin [April 2016]

  • April 2016 •
  • Report ID: 3866836



This edition presents key opinion leader (KOL) views on recent developments in the asthma market, including the clinical role of Nucala (mepolizumab; GSK) the prospects for Teva’s recently approved Cinqair (reslizumab) and the future for lebrikizumab (Roche) following the disappointing LAVOLTA trial results.

Is Nucala an alternative to Xolair?
In patients eligible for Xolair and Nucala, which antibody do KOLs pick first and why?
Does Cinqair have any role? Are there any circumstances where it is preferred over Nucala?
What is the future for anti-IL13 antibodies?
Why might Roche conduct further studies with lebrikizumab?
Industry=Therapy ParentIndustry=LifeSciences Date=201604 Publisher=FirstwordPharma Price=1000